Adoshell Islets News Today

25.09.2023 - Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, ... Seite 1

Adocia management will hold a Webcast (in French) on Thursday, March 16, 2023, at 6:30 pm CEST TEAMS Link: https://zoom.us/j/96854749555 ID meeting: 968 5474 9555 Net loss of €6.9m (€22.8m

The immediate receipt of the EUR 6 million brings Adocia's cash position to EUR 20.7 million as of today A strengthened financial situation while waiting for the reception of revenue from

The immediate receipt of the EUR 6 million brings Adocia's cash position to EUR 20.7 million as of todayA strengthened financial situation while waiting for the reception of revenue from the collaboration with Tonghua Dongbao (potential to receive USD 80 million) and for the signature of new partnershipsThese additi...

Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF")

A cash position of EUR 20.1 million as of September 30, 2022 An increase in collaboration revenues of EUR 2.3 million for the quarter, compared to EUR 0.4 million for the same period last

Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF")

Adocia management will hold a Webcast (in French) on Tuesday, September 20, 2022, at 6:00 pm CEST Net profit for the six months ended June 30, 2022, of EUR 4.25 million compared to a loss of EUR

AdoShell Islets regulated glycemic control in immunocompetent diabetic animals in a 132-day trial without the use of insulin or immunosuppression. These results will be presented at the upcoming

News and commentary from the endocrinology world